Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4588355
Max Phase: Preclinical
Molecular Formula: C22H17N3
Molecular Weight: 323.40
Molecule Type: Unknown
Associated Items:
ID: ALA4588355
Max Phase: Preclinical
Molecular Formula: C22H17N3
Molecular Weight: 323.40
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C#CCNc1ccc2nc(C)c(-c3ccc4ccccc4c3)nc2c1
Standard InChI: InChI=1S/C22H17N3/c1-3-12-23-19-10-11-20-21(14-19)25-22(15(2)24-20)18-9-8-16-6-4-5-7-17(16)13-18/h1,4-11,13-14,23H,12H2,2H3
Standard InChI Key: MTICCVZWXPWAJF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 323.40 | Molecular Weight (Monoisotopic): 323.1422 | AlogP: 4.80 | #Rotatable Bonds: 3 |
Polar Surface Area: 37.81 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 3.02 | CX LogP: 4.15 | CX LogD: 4.15 |
Aromatic Rings: 4 | Heavy Atoms: 25 | QED Weighted: 0.55 | Np Likeness Score: -1.17 |
1. Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B.. (2016) New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models., 59 (13): [PMID:27341519] [10.1021/acs.jmedchem.6b00297] |
Source(1):